Andrew Gengos
2021 - Cyteir Therapeutics
In 2021, Andrew Gengos earned a total compensation of $1.1M as Chief Business Officer at Cyteir Therapeutics, a 60% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $142,423 |
|---|---|
| Option Awards | $555,075 |
| Salary | $394,474 |
| Total | $1,091,972 |
Gengos received $555.1K in option awards, accounting for 51% of the total pay in 2021.
Gengos also received $142.4K in non-equity incentive plan and $394.5K in salary.
Rankings
In 2021, Andrew Gengos' compensation ranked 8,490th out of 12,415 executives tracked by ExecPay. In other words, Gengos earned more than 31.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,490 out of 12,415 | 32nd |
Division Manufacturing | 3,763 out of 5,508 | 32nd |
Major group Chemicals And Allied Products | 1,667 out of 2,378 | 30th |
Industry group Drugs | 1,484 out of 2,099 | 29th |
Industry Pharmaceutical Preparations | 1,105 out of 1,549 | 29th |
Source: SEC filing on April 29, 2022.
Gengos' colleagues
We found two more compensation records of executives who worked with Andrew Gengos at Cyteir Therapeutics in 2021.